HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

From executive assistant to chief executive: Charles River CEO Birgit Girshick on 'the next big transition' in the CRO industry

When Charles River Laboratories CEO Birgit Girshick started her career as an executive assistant with the company in Germany in 1989, she didn't know what was possible for her career in the world of biotech. She did know she wanted to make a difference.

By FierceBiotech · Jun 11, 2026 · via FierceBiotech
From executive assistant to chief executive: Charles River CEO Birgit Girshick on 'the next big transition' in the CRO industry

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff
The WeekFiercePharma ↗
'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevi…
Jun 12, 2026
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover
The WeekFierceBiotech ↗
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover
Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, set…
Jun 12, 2026
J&J’s Imaavy Secures Trial Win, Eyes First Approval in Warm Autoimmune Hemolytic Anemia
The WeekBriefing
J&J’s Imaavy Secures Trial Win, Eyes First Approval in Warm Autoimmune Hemolytic Anemia
Johnson & Johnson reported pivotal trial success for Imaavy in warm autoimmune hemolytic anemia, a rare diseas…
Jun 12, 2026